O N THE
MIT Sloan School of Management
What are the implications for your organization of these revolutionary innovations in pharmaceutical technology? How will they impact your efforts to reduce costs and increase profitability, develop new chemistries and promising new drug targets, make better pre-clinical decisions and better manage your R&D portfolio? What key changes will you begin to see as you move into the 21st century?
These are the issues which we will address in "The Future of the Pharmaceutical Industry," a one-and-a-half day briefing for senior corporate and technical executives on growth, change and opportunity in the pharmaceutical/biotechnology industry, to be held December 13-14, 1999, in Cambridge Massachusetts. Please accept my invitation to participate.
Led by distinguished faculty of MIT scientists, engineers and researchers, we well as noted industry experts, the program will focus on how technology is driving change in four areas:
1. Drug discovery
2. Drug development
3. Drug manufacturing, and
4. Drug evaluation
You will learn about miniaturized drug diagnosis and delivery systems, visualization tools which allow fast measurement at low concentrations, measurement technologies for facilitating the development of novel drugs, developing manufacturing strategies that will sustain you over the next decade, new quantitative techniques for evaluating product success in the marketplace, and more.
I urge you to review the enclosed prospectus, then to contact Alison Dibner, program coordinator, at (781) 239-1111 to reserve your place at the program. We look forward to seeing you in Cambridge in December.
Stan N. Finkelstein, M.D.
Co-Director, Program on the Pharmaceutical Industry
The Massachusetts Institute of Technology
Announces A Special Executive Briefing
The Future of
How New & Emerging Technologies
Are Revolutionizing Drug Development, Discovery,
Manufacturing & Evaluation
A One-and-a Half Day Program for Senior Technical
and Corporate Management
In Cambridge, Massachusetts
December 13-14, 1999
On the State of the Industry
In 1991, an ambitious project was undertaken at MIT to create an interactive research center to explore the factors that drive, constrain, and enhance the performance and competitiveness of the pharmaceutical/biotechnology industry. By assembling a high-quality, multi-disciplinary MIT faculty representing chemistry, life sciences, engineering, economics, and management sciences, the MIT Program on the Pharmaceutical Industry (POPI) was able to initiate some 20 successful research projects that examine crucial strategic areas facing drug and biotechnology companies today, including:
Led by faculty of senior academic and industry researchers, the program includes four panels designed to preview the impacts of emerging technological innovations on the pharmaceutical and biotechnology industry now and into the first decade of the 21st century, and to provide insights from MIT and industry experts on the implications for pharmaceutical business.
Who Should Attend
This program has been designed for senior executives in organizations affiliated with the pharmaceutical/biotechnology industry, including Chief Executive Officers; Presidents; Board Chairmen and Board Members; Executive Vice Presidents; Vice Presidents of Sales and Marketing, Manufacturing, Research and Development, Technology, Finance, and Operations; Corporate Counsel; Strategic Planners, and other executives involved with scientific, technical or management issues critical to the long-term health of the industry.
At This Program You Will Learn ...
... about evolving enabling technologies and the impacts they will have as drivers of change in the pharmaceutical and biotech industries, in areas including:
- Work being done to develop new chemistries to interrupt protein-protein interactions - and possibly create the next taxol-like drug.
- Rapid screening imaging techniques and microscopes for rapid drug screening in live cells.
- Measuring brain responses to sensory input.
- Hardware and software development for imaging and microarray scanning.
- Microfabrication and closed feedback loops in diagnostics and therapeutics, plus the use of micro robots to sense abnormal tissue and deliver drugs.
- Measurement technologies for speeding-up pre-clinical trials.
- New measurement technologies for facilitating the development of novel drugs.
- The impact on competitiveness of new innovations in manufacturing technology.
- Consolidation and outsourcing in manufacturing strategy.
- Performance metrics in assessing manufacturing performance.
- An innovative framework for making important R&D portfolio capital investment decisions.
- How advertising and scientific rivalries shape product market competition.
- The impact of health on work productivity and the economic cost benefits that can be attributed to using certain medical treatments.
- Future directions in the pharmaceutical/biotech industry.
I. Innovations in Pharmaceutical Technology: An Introduction
Pierre Azoulay, Program on the Pharmaceutical Industry, Massachusetts Institute of Technology
Iain Cockburn, Professor, Boston University School of Management and member of the National Bureau of Economic Research
Charles L. Cooney, Professor, Chemical and Biochemical Engineering; Executive Office Department of Chemical Engineering; and Co-Director, Program on the Pharmaceutical Industry, Massachusetts Institute of Technology
Stan N. Finkelstein, M.D., Co-Director, Program on the Pharmaceutical Industry and Senior Research Scientist, Sloan School of Management, Massachusetts Institute of Technology
Dr. Chris Hitchcock, Director, Preclinical Drug Development, Pfizer Central Research, England
Ian Hunter, Professor of Mechanical Engineering and Professor of Bioengineering, Massachusetts Institute of Technology
Klavs F. Jensen, Professor of Materials Science and Engineering and Lammot du Pont Professor of Chemical Engineering, Department of Chemical Engineering, Massachusetts Institute of Technology
Robert S. Pindyck, Mitsubishi Bank Professor of Economics and Finance, Sloan School of Management, Massachusetts Institute of Technology
Dr. G. K. Raju, Program on the Pharmaceutical Industry, Massachusetts Institute of Technology
Robert H. Rubin, M.D., Osborne Professor of Health Sciences and Technology and Director, Center for Experimental Pharmacology and Therapeutics, Harvard-MIT Division of Health Sciences and Technology; and Professor of Medicine and Chief of Surgical and Transplant Infectious Disease, Department of Medicine, Massachusetts General Hospital
Anthony J. Sinskey, Professor of Microbiology, Department of Biology, Massachusetts Institute of Technology
Peter K. Sorger, Howard and Linda Stern Career Development Associate Professor of Biology, Department of Biology, Massachusetts Institute of Technology
Matthew A. Wilson, Robert A. Swanson Assistant Professor of Biology,
Department of Biology, Massachusetts Institute of Technology
About the MIT Program on the Pharmaceutical Industry
The MIT Program on the Pharmaceutical Industry (POPI) is a unique university-industry-government
partnership based at MIT's Sloan School of Management. It was founded in
1991 to both perform multidisciplinary research into the factors that drive,
constrain and enhance the performance and competitiveness of the pharmaceutical/biotechnology
industry, and to educate future scientific and management leaders for the
industry and for those organizations that supply it, regulate it or use
its products. Among its research and educational accomplishments, which
involve more than 30 faculty from throughout the MIT community, POPI continues
to track ongoing work in areas including drug development, pharmaceutical
manufacturing, and the pharmaceutical marketplace.
Please complete and return this entire page to Alison Dibner, Center for Management Research (conference administration office), 55 William Street, Wellesley, MA 02181, or call Ms. Dibner at (781) 239-1111. You may also fax this page to (781) 239-1546. Confirmation of receipt will be made by mail.
The registration fee is $1,250. It includes luncheons, reception, and complete program materials. It does not include hotel accommodations.
Accommodations: We have reserved a block of rooms at a hotel convenient to the program site. Information on how you may arrange for accommodations will be sent to you approximately 8 weeks prior to the session.
Certificates: Certificates of Participation will be awarded to all those attending the Program.
Attendance Limitations: Attendance will be reserved on a first-come, first-served basis. If a session is canceled, MIT's liability is limited to the registration fee.
Return this form to Ms. Alison Dibner, Center for Management Research, 55 William Street, Wellesley MA 02181, or Tel. (781) 239-1111; Fax: (781) 239-1546
[ ] Please register me for the December 13-14, 1999, MIT executive briefing on The Future of the
Team Registration: Others attending with me include:
(please note if addresses of those on team differ)
[ ] Check enclosed. (Please make payable to CMR/POPI.)
[ ] Please bill me. Payment is requested prior to session.
[ ] Confirming earlier registration by phone.
[ ] I cannot attend the program
on the date listed, but would like to be notified of future executive programs
offered by the MIT Program on the Pharmaceutical Industry.
Please send comments and suggestions to email@example.com
[MIT Sloan School of Management]